The clinical efficacy of purple passion fruit peel extract (a flavonoid-rich dietary supplement) in reducing cardiovascular risk factors in adult type 2 diabetic subjects was investigated in a randomized, double-blind, placebo-controlled trial. Forty-one subjects were randomly assigned to receive a daily dose of purple passion fruit (220 mg) or a matched placebo for 16 weeks. Body mass index, blood pressure, fasting and postprandial blood glucose, glycated hemoglobin, and lipid profile were determined at baseline and at monthly intervals. A significant reduction in systolic blood pressure and fasting blood glucose was observed following administration of purple passion fruit ( P < .05). Purple passion fruit was well tolerated, and no adverse events were reported. These data suggest that purple passion fruit supplementation for 16 weeks in type 2 diabetics results in a significant reduction in systolic blood pressure and fasting blood glucose, indicating that purple passion fruit is safe and well tolerated by diabetics.

No abstract

In the present study, hepatic tumors were chemically induced in male Wistar Albino rats with Diethylnitrosamine. Hepatic ultrasonography was performed to detect the development of hepatic tumors clinically at the end of treatment period. In sonography, the presence of tumor nodules was appreciated as the indistinct hepatic borders and circumscribed varied echogenicity with distinct hyperechoic borders in the affected portion of liver in contrast to the liver of negative control rats which showed distinct borders, homogenous parenchyma and medium echogenicity.